Zura Bio Q3 2026: Cash Falls to $187.7M, Loss Widens to $76.4M; HS Data Due Q4
ZURA is trading near its 52-week low of $3.25 (11% above the low).
Summary
Zura Bio ended Q3 2026 with $187.7 million in cash, enough to fund operations through at least the end of 2028, while its nine-month net loss widened to $76.4 million. The hidradenitis suppurativa Phase 2 topline is still expected in Q4 2026.
Key Events · Earnings and Guidance · ZURA
-
Q3 Cash Position and Runway
Cash and cash equivalents stood at $187.7 million at September 30, 2026, down from $205.1 million at the prior 10-Q; management says this funds operations through at least the end of 2028.
-
Nine-Month Loss Widens
Net loss was $76.4 million for the nine months ended September 30, 2026 versus $51.5 million a year earlier, driven by R&D of $54.9 million (up 77% from $31.1 million).
-
HS Phase 2 Topline Due Q4 2026
TibuSHIELD enrollment is complete at 247 participants, exceeding target; topline results are expected in the fourth quarter of 2026.
-
SSc and PMR Timelines
TibuSURE SSc enrollment is complete at 91 participants with topline expected in the first half of 2027; the PMR Phase 2 IND was cleared by the FDA with study initiation planned for year end 2026.
Analysis · ZURA · Life Sciences
Zura burned $59.3 million of operating cash in the first nine months of 2026, leaving $187.7 million at September, down from $205.1 million at the Q2 report. Management still says that cash funds operations through at least the end of 2028, so there is no near-term financing need — but the loss widened to $76.4 million from $51.5 million a year earlier as the tibulizumab Phase 2 trials in hidradenitis suppurativa and systemic sclerosis scaled up. The binary event is the TibuSHIELD HS topline, expected in Q4 2026; the SSc readout follows in the first half of 2027, and a PMR study is planned to start around year end 2026.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 31% of the 1656 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ZURA was trading at $3.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $341.2M. The 52-week trading range was $3.25 to $7.44. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.